Patents by Inventor Amy E. Rabideau

Amy E. Rabideau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA POLYMERASE VARIANTS
    Publication number: 20240102066
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: August 11, 2023
    Publication date: March 28, 2024
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • High fidelity in vitro transcription
    Patent number: 11851694
    Abstract: The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: December 26, 2023
    Assignee: ModernaTX, Inc.
    Inventors: David Mauger, Vladimir Presnyak, Amy E. Rabideau, Iain Mcfadyen
  • RNA polymerase variants
    Patent number: 11767548
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 26, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL CAPPING
    Publication number: 20230104080
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Application
    Filed: August 1, 2022
    Publication date: April 6, 2023
    Applicant: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • RNA polymerase variants for co-transcriptional capping
    Patent number: 11485960
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: November 1, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith, Michelle Lynn Hall
  • FED-BATCH IN VITRO TRANSCRIPTION PROCESS
    Publication number: 20220145381
    Abstract: The present disclosure provides methods of in vitro transcribing a ribonucleic acid (RNA) of interest. In some embodiments, such methods include determining consumption rates of nucleoside triphosphates (NTPs).
    Type: Application
    Filed: March 11, 2020
    Publication date: May 12, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Joseph Elich, Amy E. Rabideau, Michael Shamashkin, Rosalie Philpot, Brian Fritz, Peter Wojciechowski
  • HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
    Publication number: 20220096522
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by inproved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 31, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
    Publication number: 20220096521
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Application
    Filed: November 10, 2021
    Publication date: March 31, 2022
    Applicant: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • RNA POLYMERASE VARIANTS
    Publication number: 20210395792
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 23, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • High purity RNA compositions and methods for preparation thereof
    Patent number: 11202793
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: December 21, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL CAPPING
    Publication number: 20210309976
    Abstract: The present disclosure provides RNA polymerase variants for high efficiency transcription.
    Type: Application
    Filed: May 20, 2021
    Publication date: October 7, 2021
    Applicant: ModernaTX, Inc.
    Inventors: Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith
  • RNA polymerase variants
    Patent number: 11066686
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: July 20, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • High purity RNA compositions and methods for preparation thereof
    Patent number: 10653712
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: May 19, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • RNA POLYMERASE VARIANTS
    Publication number: 20200131550
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 30, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • RNA polymerase variants
    Patent number: 10526629
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 7, 2020
    Assignee: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • RNA POLYMERASE VARIANTS
    Publication number: 20190309337
    Abstract: The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
    Type: Application
    Filed: June 5, 2019
    Publication date: October 10, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
  • HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
    Publication number: 20190247417
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 15, 2019
    Applicant: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
    Publication number: 20180363019
    Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by inproved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.
    Type: Application
    Filed: June 6, 2018
    Publication date: December 20, 2018
    Applicant: ModernaTX, Inc.
    Inventors: Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
  • Protein retrosplicing enabled by a double ligation reaction
    Patent number: 9731029
    Abstract: Proteins containing a C-terminal thioester are important intermediates in semi-synthesis. Currently there is one main method for the synthesis of protein thioesters that relies upon the use of engineered inteins. The invention involves, in some aspects a method, utilizing Sortase A, for preparation of recombinant proteins containing a C-terminal ?thioester. This new method for double ligatation is useful for synthesizing new or naturally occurring molecules such as a protein thioester.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: August 15, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley L. Pentelute, Xiaoli Liao, Amy E. Rabideau, Jingjing Ling, Rocco L. Policarpo
  • TRANSLOCATION OF NON-NATURAL CHEMICAL ENTITIES THROUGH ANTHRAX PROTECTIVE ANTIGEN PORE
    Publication number: 20170049906
    Abstract: Disclosed is a new approach for delivering compounds and drugs to the cytosol of living cells through the use of engineered protein transporters. The engineered protein transporters include a pore and a pore specific delivery protein, wherein a reagent such as a drug is attached to one or more of the engineered protein transporters.
    Type: Application
    Filed: November 1, 2016
    Publication date: February 23, 2017
    Applicants: President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: Xiaoli Liao, Amy E. Rabideau, Bradley L. Pentelute, Jingjing Ling, Gizem Akçay, John Collier